Live feed
·
PRReleasevia Quantisnow
iBio Inc. logo

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

ByQuantisnow·Wall Street's wire, on your screen.
IBIO· iBio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IBIO (iBio Inc.) and more on Quantisnow.